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Neurotrophic gene polymorphisms and response
to psychological therapy
KJ Lester1, JL Hudson2, M Tropeano1, C Creswell3, DA Collier1, A Farmer1, HJ Lyneham2, RM Rapee2 and TC Eley1
Therapygenetics, the study of genetic determinants of response to psychological therapies, is in its infancy. Here, we investigate
whether single-nucleotide polymorphisms in nerve growth factor (NGF) (rs6330) and brain-derived neutrotrophic factor
(BDNF) (rs6265) genes predict the response to cognitive behaviour therapy (CBT). Neurotrophic genes represent
plausible candidate genes: they are implicated in synaptic plasticity, response to stress, and are widely expressed in brain
areas involved in mood and cognition. Allelic variation at both loci has shown associations with anxiety-related phenotypes. A
sample of 374 anxiety-disordered children with white European ancestry was recruited from clinics in Reading, UK, and in Sydney,
Australia. Participants received manualised CBT treatment and DNA was collected from buccal cells using cheek swabs. Treatment
response was assessed at post-treatment and follow-up time points. We report first evidence that children with one or more
copies of the T allele of NGF rs6330 were significantly more likely to be free of their primary anxiety diagnosis at follow-up
(OR¼ 0.60 (0.42–0.85), P¼ 0.005). These effects remained even when other clinically relevant covariates were accounted for
(OR¼ 0.62 (0.41–0.92), P¼ 0.019). No significant associations were observed between BDNF rs6265 and response to psychological
therapy. These findings demonstrate that knowledge of genetic markers has the potential to inform clinical treatment decisions for
psychotherapeutic interventions.
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Introduction
Anxiety disorders frequently onset in childhood1 are highly
prevalent2 and often persist into adolescence and adulthood.3
They are associated with a wide range of impairments4–6 and
are a major risk factor for future psychological7 and physical
health problems.8 Given the considerable suffering, dysfunc-
tion and poor prognosis associated with child anxiety,
ensuring that treatments are maximally efficacious is of critical
importance.
Remission rates in the most established first-line treatment for
child anxiety, cognitive behavior therapy (CBT), are approxi-
mately 55% immediately post treatment, rising to around 65%
by 6–12-month follow-up.9 This means that 35–45% of children
retain significant impairments following treatment. Only limited
work has investigated the predictors of children’s treatment
response to CBT, despite the potential of such an approach to
guide treatment and improve outcome. The most convincing
predictors are increased symptom severity,10 parental psycho-
pathology11,12 and comorbid mood disorders.13
While the field of pharmacogenetics is well established,14
therapygenetics, the study of genetic markers that predict
response to psychological therapy, is a novel research area.
In the most comprehensive study to date,15 we showed that
anxiety-disordered children (N¼ 270) with the 5-HTTLPR SS
genotype were 20% more likely to be free of their primary
anxiety diagnosis following CBT than those with SL/LL
genotypes. 5-HTTLPR SS genotype predicted better treat-
ment response even after controlling for other significant
clinical covariates. However, this effect was seen only at
follow-up (assessed at 3, 6 or 12 months) and not immediately
post treatment. Similarly, the SS genotype (and S/Lg and Lg/
Lg) predicted increased sensitivity to an experimental atten-
tion bias modification intervention designed to manipulate
attentional biases either toward threat or toward positive
stimuli.16 However, another study with adult bulimia patients
found that the 5-HTTLPRS allele predicted a poorer treatment
response, irrespective of whether it was CBT, medication or
combined therapy.17 The contradictory results between Eley
et al.15 and Steiger et al.17 most likely reflect small samples,
varying phenotypes and the use of medication. Finally, an
association was observed between COMT val158met and
CBT response in adult panic disorder;18 however, many
patients also received medication. A recent review argues
strongly for incorporating genetic variation into psychological
treatment research given its potential to shed light on
psychopathology, enhance the ability to tailor personalised
treatments on the basis of genetic profile and improve
treatment efficacy.19
Building on the very modest therapygenetics literature so
far, this study examines associations between polymorphisms
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in nerve growth factor (NGF rs6330, also referred to
as 104C4T) and brain-derived neutrotrophic factor (BDNF
rs6265, also referred to as Val66Met) and response to CBT
in a sample of anxiety-disordered children. In brief, both
NGF and BDNF are neurotrophic genes that regulate growth
factors involved in the development, differentiation and
survival of neurons. Neurotrophic markers are plausible
candidates for involvement in response to psychological
therapy. They have a key role in synaptic plasticity and long-
term potentiation, are implicated in the orchestration of HPA
axis response to stress and are widely expressed in limbic
areas of the central nervous system (for example, hippocam-
pus, insula, anterior cingulate cortex) involved in mood
and cognition.20 Reduced neurotrophic signalling and neuro-
trophin-mediated neuronal plasticity may be implicated in
the pathophysiology of a range of psychiatric disorders and
their therapy.21–23
A non-synonymous single-nucleotide polymorphism in the
NGF gene, rs6330, produces an alanine to valine substitution
at amino acid position 35, and is thought to affect intracellular
processing and secretion ofNGF.24 Studies in rodent and non-
human primates have shown that NGF (and BDNF) levels are
sensitive to environmental influences, such as maternal
separation, deprivation and changes to the rearing environ-
ment.25–27 NGF blood levels also increase in response to
anxiety and acute arousal states in humans.28,29 NGF serum
levels also rise in response to positive environments, namely,
after successful but not unsuccessful CBT treatment for
generalised anxiety disorder.30 Allelic variations at the rs6330
locus have previously shown associations with anxiety-related
traits and affective disorders. NGF genotype interacted with
gender to predict trait-anxiety scores, with higher anxiety seen
in females with the CC genotype compared with CT and TT
genotype carriers, but with the opposite effect observed in
males.31 In contrast, the T allele of rs6330 has been associated
with affective disorders in females.32
BDNF secretion is activity dependent, with decreases
associated with stress and mood disorders, whereas anti-
depressant treatment increases BDNF secretion.22,33–35 In
the functional rs6265 (Val66Met) polymorphism, the more
common G allele encodes for valine (Val), whereas the A
allele encodes for methionine (Met). The Met allele is
associated with diminished activity-dependent secretion of
BDNF,36,37 structural brain abnormalities in limbic regions of
the central nervous system,38–40 impaired hippocampal
activity,41 impaired associative fear learning,42 and, in
knock-in mice, defective BDNF secretion and increased
anxiety-related behaviour.37
Association studies in humans have yielded heterogenous
findings with regard to determining the risk allele for anxiety-
related traits. Some studies have reported an association
between the Val66 allele and higher neuroticism scores;43,44 a
meta-analysis concluded that the Met variant, despite its
unfavourable biological effects, was associated with lower
neuroticism.45 Others have reported no significant association
between either allele and neuroticism scores.46–48 However,
others report significant associations between Met carriers
and increased introversion,49 harm avoidance50 and signifi-
cant gene–gene (for example, with 5-HTTLPR) and gene–
environment interactions for anxiety and depression-related
(endo)phenotypes.49,51–54 A better antidepressant treatment
response is also observed for the Met variant.55
To date, no studies have investigated whether neurotrophic
gene polymorphisms predict response to purely psychological
therapy, despite NGF and BDNF being associated with
anxiety responses in humans and neural plasticity and BDNF
appearing to mediate antidepressant treatment response.
Furthermore, given our recent finding that 5-HTTLPR
genotype predicts treatment response to CBT, evidence of
genetic epistasis between 5-HTTLPR and neurotrophic
markers (particularly BDNF Val66Met) and a role for BDNF
in mediating serotonergic antidepressant response, it is also
of interest to explore whether neurotrophic gene polymorph-
isms interact with 5-HTTLPR to predict treatment response.
Here, we test these novel hypotheses in a sample of anxiety-
disordered children aged 6–13 years receiving CBT.
Materials and methods
Participants. Six hundred and thirteen children aged 6–13
years and meeting the DSM-IV56 criteria for a primary
anxiety-disorder diagnosis were recruited (participation
rate¼ 73%). Exclusion criteria were significant physical/
intellectual impairment and psychoses. Genotyping data
were available for 593 children for NGF rs6330 and 604
children for BDNF rs6265. Parental DNA was obtained from
525 mothers and 457 fathers for rs6330, and from 583
mothers and 458 fathers for rs6265, with 414 and 424
complete trios for rs6330 and rs6265, respectively.
Recruitment was done at two clinical sites: Sydney, Australia
and Reading, UK. The Australian sample was recruited from
referrals to randomised CBT-based treatment trials under-
taken by the Centre for Emotional Health at Macquarie
University (N¼ 429). The UK sample was recruited from two
CBT-based clinical trials at the Berkshire Child Anxiety Clinic,
University of Reading (N¼ 156) and a feasibility study of CBT-
based guided self-help within the Oxfordshire Primary Child
and Adolescent Mental Health Service (N¼ 24). Treatment
was based on the Cool Kids Program.57
Children’s ethnicity was assessed using the ancestry of their
grandparents. Those with four grandparents of white European
ancestry were included in the ‘white’ subgroup (N¼ 374) and
data from this subset are analysed here. Sample descriptives
for this sample are reported in Table 1. This sample overlaps to
a significant extent with the sample reported in our earlier paper
on the associations between treatment response and the
5-HTTLPR.15 Fifteen extra cases are included in this paper for
whom genotype data were available for rs6330 and/or rs6265
but who were not included in our earlier paper because of not
having 5-HTTLPR genotype data. The numbers of subjects
from other ethnic subgroups were too small for a separate
analysis (African or Caribbean, N¼ 2; Asian, N¼ 14; Arab and
Middle Eastern, N¼ 9; Mixed, N¼ 41; ancestry unknown and
missing data, N¼ 173).
Controls consisted of 459 white Europeans (61% female,
mean age±s.d., 31.95±12.62) recruited for the Bipolar
Affected Case–Control study.58 Participants were excluded
if they, or a first-degree relative, ever fulfilled the criteria or
received treatment for any psychiatric disorder.
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Measures. Child diagnoses were made using the Anxiety
Disorders Interview Schedule for DSM-IV, Parent and Child
Versions (ADIS-IV-C/P59), and based on composite parent/
child report and clinician severity rating (CSR; 0–8).
Diagnostic criteria were applied by graduate or clinical
psychologists, with diagnosis assigned when the child met
the diagnostic criteria and received a CSR of 4 or more. Inter-
rater reliability across diagnostic subtypes was excellent at
both sites (40.80 for anxiety disorders, 40.65 for mood
disorders).60,61 The percentages of children with specific
disorders as their (a) primary diagnosis or (b) anywhere in
their profile were as follows: separation anxiety disorder
(18.7%, 48.5%); social phobia (20.9%, 62.5%); generalised
anxiety disorder (44.7%, 79.9%); specific phobia (9.4%,
56.7%); panic/agoraphobia (0.8%, 3.0%); obsessive com-
pulsive disorder (3.5%, 10.5%); post-traumatic stress disorder
(0.3%, 0.8%) and anxiety disorders not otherwise specified
(1.9%, 2.1%). Mood disorders were present in 10.2% of the
children (depression: 3.5%; dysthymia: 6.7%), with attention
deficit hyperactivity disorder present in 11.5% and
oppositional defiant disorders in 12.1% of the children.
Maternal and paternal depression, anxiety and stress over
the past week at the pretreatment time point were assessed
using the self-report Depression, Anxiety and Stress Scale
(DASS-21) (ref. 62). Three subscales consisting of 7 items
each were calculated: stress, anxiety and depression, with
scores for each subscale ranging from a possible 0 to 42
(subscale totals are multiplied by 2). Internal consistency for
each scale was 0.85, 0.77 and 0.89, respectively. For the
purpose of the analyses reported here, a single mean score
across the three subscales was computed.
Genotyping. Genomic DNA was extracted from buccal
swabs (for cases) and blood samples (for controls) using
established procedures.63,64 Genotyping was performed
using the Sequenom MassARRAY iPLEX Gold technology
(Sequenom, San Diego, CA, USA). Primers for PCR
amplification and extension probes were purchased from
Metabion (Martinsried, Germany). PCR and extension
reactions were performed according to the iPLEX Gold
protocol, with 10 ng of genomic template per sample.
Extension products were analysed on a compact MALDI-
TOF Mass Spectrometer (Sequenom). Genotypes were
assigned automatically using the MassARRAY SpectroTyper
4.0 software (Sequenom) and then individually inspected in
order to remove erroneous calls. Quality control measures
included eight negative controls per 384-well plate and 4% of
samples genotyped in duplicate to confirm inter-plate
reproducibility. The genotyping success rate was 98.1% for
rs6330 and 99% for rs6265. Genotype distribution conformed
to the Hardy–Weinberg equilibrium for rs6330 (w21¼ 0.56,
P¼ 0.453) and rs6265 (w21¼ 0.05, P¼ 0.823).
Procedure. Ethical approval was granted at each site by
Human Ethics and Biosafety Committees (National Research
Ethics Service: Berkshire Research Ethics Committee and
Macquarie University Ethics Review Committee (Human
Research)). Informed consent was sought from parents and
verbal assent from children. Buccal swabs were collected
either at the clinic or through the post. Diagnostic data were
available before and after treatment (N¼ 336 children;
89.8%) and at one follow-up point (N¼ 278; 74.3%). The
timing of the follow-up differed across trials (3, 6 and 12
months) and for these the N (percentage) values were
as follows: 41 (11.0%), 217 (58.0%) and 20 (5.3%) available
at the 3-, 6- and 12-month follow-up points, respectively
Those without follow-up data differed from those with follow-up
data by being significantly more likely to have a comorbid
mood disorder (w21¼ 10.44, P¼ 0.001, 18.8% vs 7.2%), being
significantly older (t(372)¼ 2.94, P¼ 0.003, 9.93 vs 9.30
years) and having a less severe primary anxiety disorder
before treatment (t(372)¼2.41, P¼ 0.016, 5.96 vs 6.23).
Statistical analyses. The primary outcome was treatment
response for primary anxiety diagnosis at follow-up using an
additive genotype model. We note whether any effects
survive multiple testing correction using a Bonferroni
adjusted P value of 0.017 correcting for the analysis of
Table 1 Sample characteristics for the white subset and by treatment site
White sample
(N¼374)
Sydney subset
(N¼ 262)
Reading subset
(N¼112)
t/v2 d.f. P
Pre-treatment
Child agea 6–13; 9.46 (1.82) 6–13; 9.45 (1.92) 6–12; 9.47 (1.59) 0.10 251e 0.927
Child gender (m:f) 188:185d 134:127 54:58 0.31 1 0.580
NGF genotype frequencies (CC; CT; TT)b 29.5; 47.8; 22.7 28.8; 48.1; 23.1 31.1; 47.2; 21.7 0.21 2 0.901
BDNF genotype frequencies (GG; GA; AA)b 67.5; 29.5; 3.0 69.3; 27.2; 3.4 63.0; 35.2; 1.9 2.76 2 0.251
Primary disorder severitya 4–8; 6.16 (0.95) 4–8; 6.43 (0.83) 4–8; 5.53 (0.91) 9.36 372 0.000
Post-treatment
Primary disorder severitya 0–8; 3.15 (2.09) 0–8; 3.43 (1.85) 0–8; 2.39 (2.48) 3.66 131e 0.000
Primary anxiety responders (N¼336)c 174 (51.8) 125 (51.2) 49 (53.3) 0.11 1 0.740
All anxiety responders (N¼336)c 126 (37.3) 93 (38.1) 33 (35.1) 0.26 1 0.608
Follow-up
Primary disorder severitya 0–8; 2.73 (2.06) 0–7; 3.05 (1.87) 0–8; 1.58 (2.30) 4.52 80e 0.000
Primary anxiety responders (N¼278)c 175 (62.9) 135 (61.6) 40 (67.8) 0.75 1 0.385
All anxiety responders (N¼278)c 128 (46.0) 99 (45.2) 29 (49.2) 0.29 1 0.589
Abbreviations: BDNF, brain-derived neutrotrophic factor; f, female; m, male; NGF, nerve growth factor.
Note. Data provided are: arange; mean (s.d.); bpercentages; cN (percentage); dgender not reported for one case; eWelch–Satterthwaite corrected d.f.
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three independent markers, investigated in this and our
previous paper.15 Only when the additive model retained
significance after applying multiple testing corrections do we
report recessive and dominant genetic models. No further
correction is applied, because these are not independent
tests. We also report treatment response data at post
treatment and for all anxiety diagnoses, for subsets of the
data (for example, only those with follow-up data at 6 months)
and interactions with 5-HTTLPR. We do not apply further
multiple testing corrections, because these are supplementary
analyses that test the same core hypothesis and are not fully
independent tests. Finally, we present secondary analyses
investigating case–control and family-based associ-
ations. We do not apply multiple testing corrections for these
secondary analyses. Stringently correcting for all primary and
secondary analyses presented on the three markers
described here and in our previous paper with the
5-HTTLPR would require a Bonferroni adjusted P value of
0.002. None of the analyses reported here would survive this
correction. However, we consider this to be very conservative
given that the vast majority of analyses performed for each
marker do not represent independent tests.
Results
Treatment response analyses. Treatment response was
classified as (1) primary anxiety response: the absence of the
primary anxiety disorder and (2) all anxiety response: the
absence of any anxiety diagnosis. Treatment response was
assessed immediately post treatment and at follow-up
(collapsed across the time point, although usually 6 months
after the end of treatment, with a proportion assessed at 3
and 12 months post treatment). We used logistic regression
analyses with robust standard errors and maximum
likelihood estimation to test for differences in treatment
response using the additive genetic model. No significant
effects of genotype were observed immediately post
treatment for either polymorphism (see Table 2).
For NGF genotypes, a significant difference in treatment
response was observed for primary anxiety response at
follow-up (Table 2). This effect was significant for the additive
model and supported by inspection of frequency data, with
each extra T allele conferring a more positive treatment
response (OR¼ 0.60 (95% CI: 0.42–0.85), P¼ 0.005), with
this effect surviving multiple testing corrections. As shown in
Figure 1, 53.2% of those with the CC genotype were free of
their primary anxiety diagnosis and 63.5% of those with the CT
genotype showed a positive treatment response, while 76.7%
of those with the TT genotype were free of their primary
anxiety diagnosis at follow-up. As the additive model survived
multiple testing corrections, analyses were performed for
recessive and dominant genetic models. A significant effect of
NGF genotype was also observed in both models (recessive:
OR¼ 0.45 (0.23–0.87), P¼ 0.018; dominant: OR¼ 0.55
(0.32–0.93), P¼ 0.026). For all anxiety response, the additive
model indicated a non-significant statistical trend (OR¼ 0.73
(0.52–1.02), P¼ 0.067), with the percentage of treatment
responders for each genotype as follows: CC: 40.5%; CT:
45.3%; TT: 56.7% (see Figure 1). No significant effects of the
BDNF polymorphism on treatment response were observed
(see Table 2).
Next we determined whether the significant effect of NGF
genotype remained even after controlling for other possible
covariates. As a first stage, genotype (CC coded as 1, CT
coded as 0, TT coded as 1), time (linear and quadratic terms to
account for the use of three different follow-up time points),
age, gender and treatment site (Sydney or Reading) were
entered into the model. For primary anxiety response only
NGF genotype was a significant predictor (OR 0.58 (0.40–
0.84), P¼ 0.004, see Table 3, model 1), indicating that with
each additional T allele children were significantly less likely to
have their primary anxiety disorder at follow-up. This effect
survived multiple testing corrections. This pattern of findings
was also similar when analyses were performed on (a) the
entire sample (that is, white subsetþ other ethnicities)
(OR¼ 0.72 (0.54–0.96), P¼ 0.024); (b) those with 6-month
follow-up only (OR¼ 0.64 (0.42–0.97), P¼ 0.037) and (c)
those who received an eight session in-person CBT pro-
gramme (OR¼ 0.61 (0.41–0.92), P¼ 0.018). In a subsequent
model (Table 3, model 2), we included other variables that
were significant predictors of treatment response (comorbid
mood disorders, pretreatment symptom severity and mater-
nal psychopathology were significant predictors, paternal
Table 2 Genotypic frequencies and logistic regression analyses for NGF rs6330 and BDNF rs6265 by treatment response (additive model coded as: 1, 0, 1)
Time Model A1/A1 A1/A2 A2/A2 Additive
N (%) N (%) N (%) OR (95% CI) P
NGF rs6330
Post-treatment Primary anxiety responders 46 (47.9) 87 (54.7) 40 (53.3) 0.88 (0.66–1.20) 0.443
All anxiety responders 34 (35.1) 63 (39.6) 28 (37.3) 0.94 (0.69–1.28) 0.714
Follow-up Primary anxiety responders 42 (53.2) 87 (63.5) 46 (76.7) 0.60 (0.42–0.85) 0.005
All anxiety responders 32 (40.5) 62 (45.3) 34 (56.7) 0.73 (0.52–1.02) 0.067
BDNF rs6265
Post-treatment Primary anxiety responders 113 (50.2) 54 (54.5) 4 (44.4) 0.92 (0.61–1.38) 0.694
All anxiety responders 87 (38.5) 33 (33.0) 3 (33.3) 1.22 (0.79–1.88) 0.361
Follow-up Primary anxiety responders 122 (64.2) 48 (61.5) 3 (42.9) 1.24 (0.78–1.98) 0.358
All anxiety responders 85 (44.7) 38 (48.7) 3 (42.9) 0.91 (0.58–1.43) 0.670
Abbreviations: BDNF, brain-derived neutrotrophic factor; NGF, nerve growth factor.
Bold values indicate Po0.05.
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psychopathology was not a significant predictor) in their own
right. Importantly, NGF genotype remained a significant
predictor of treatment response for primary anxiety response
when controlling for these other factors (OR ¼ 0.62 (0.41–
0.92),P¼ 0.019); see Table 3. However, this effect marginally
exceeded the Bonferroni-corrected P-value. For the more
stringent test of all anxiety response, the effect size was
similar but non-significant (OR¼ 0.71 (0.50–1.00), P¼ 0.051,
see Table 3).
Interaction with 5-HTTLPR. Using multiple logistic
regression analyses with robust standard errors and maxi-
mum likelihood estimation, we investigated the interaction
between (i) BDNF genotype (AA/AG coded as 1, GG coded as
0 as the dominant model was most strongly indicated
by frequency data) and 5-HTTLPR genotype (SS coded as 1,
SL/LL coded as 0) and (ii) NGF genotype (CC coded as 1,
CT coded as 0, TT coded as 1) and 5-HTTLPR genotype as
predictors of primary anxiety response at follow-up. The basic
model included genotypes, time (linear and quadratic terms),
age, gender and treatment site (see Table 4, model 1).
For rs6265 there was no significant main effect (OR¼ 0.99
(0.56–1.78), P¼ 0.983) or interaction with 5-HTTLPR
(OR¼ 2.43 (0.48–12.33), P¼ 0.285). The inclusion of
rs6265 in the model did not diminish the predictive power of
5-HTTLPR (OR¼ 0.31 (0.12–0.75), P¼ 0.010), with this
effect surviving multiple testing corrections.
As main effects (that is, no interaction term in the model),
both NGF genotype and 5-HTTLPR significantly predicted
treatment response (NGF: OR¼ 0.58 (0.40–0.84), P¼ 0.004;
5-HTTLPR: OR¼ 0.38 (0.18–0.80), P¼ 0.011, see Table 4,
model 1), with both effects surviving multiple testing correc-
tions. Adding an interaction term did not reduce the predictive
power of either NGF (OR¼ 0.57 (0.38–0.85), P¼ 0.006) or
5-HTTLPR (OR¼ 0.39 (0.18–0.85), P¼ 0.017, see Table 4,
model 2). The interaction term was non-significant (OR¼ 1.12
(0.40–3.12),P¼ 0.823) and was therefore omitted from model
3. In model 3, the significant effect of both markers
was retained even after controlling for other significant
clinical covariates (NGF: OR¼ 0.59 (0.39–0.89), P¼ 0.013;
5-HTTLPR: OR¼ 0.36 (0.16–0.82), P¼ 0.015).
Case–control and family-based analyses. Genotypic
frequencies were compared between cases (N¼ 374) and
never-psychiatrically-ill controls (N¼ 459). There were no
significant differences using the additive model and no other
genetic models were indicated for either rs6265 ((GG, GA,
AA); cases: 67.5%, 29.5%, 3.0% and controls: 64.3%,
32.7%, 3.1%, P¼ 0.388) or rs6330 ((CC, CT, TT); cases:
29.5%, 47.8%, 22.7% and controls: 30.3%, 50.8% 19.0%,
P¼ 0.363). Within-family analyses using transmission-
disequilibrium tests (TDT) on the trios from the case
sample only (child, mother and father; N¼ 273 (rs6330)
and N¼ 278 (rs6265)) were also non-significant (rs6330:
w2
2
¼ 0.09, P¼ 0.763; rs6265: w2
2
¼ 0.62, P¼ 0.429).
Discussion
Children with a primary anxiety disorder with one or more
copies of the NGF rs6330 T allele were significantly more
likely to be free of their primary anxiety diagnosis at follow-up.
We observed an additive effect, with each extra T allele
Figure 1 Percentage of children free of primary anxiety disorder and all
anxiety disorders at follow-up by nerve growth factor rs6330 genotype (error
bars±1 s.e.).
Table 3 Predicting response to CBT in anxious children: presence of primary anxiety disorder and all anxiety disorders at follow-up (NGF rs6330 coded as CC¼1;
CT¼ 0, TT¼1)
Predictor variable Model 1 Model 2
Primary anxiety
disorder
All anxiety
disorders
Primary anxiety
disorder
All anxiety
disorders
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
NGF rs6330 genotype 0.58 (0.40–0.84) 0.004 0.71 (0.50–1.00) 0.051 0.62 (0.41–0.92) 0.019 0.78 (0.53–1.14) 0.202
Time (linear) 0.21 (0.02–1.99) 0.175 0.23 (0.03–2.01) 0.183 0.44 (0.04–5.01) 0.508 0.35 (0.03–3.60) 0.378
Time2 (quadratic) 1.27 (0.93–1.74) 0.135 1.24 (0.91–1.68) 0.170 1.14 (.81–1.60) 0.449 1.17 (0.84–1.62) 0.356
Age 0.89 (0.77–1.03) 0.109 0.93 (0.82–1.07) 0.321 0.89 (0.76–1.05) 0.157 0.95 (0.81–1.10) 0.490
Gender 1.26 (0.75–2.09) 0.384 1.29 (0.79–2.09) 0.311 1.34 (0.76–2.38) 0.311 1.31 (0.75–2.30) 0.336
Site 1.16 (0.61–2.22) 0.654 1.05 (.57–1.90) 0.884 0.96 (0.44–2.09) 0.918 0.69 (0.33–1.46) 0.337
Pre-treatment severity 1.53 (1.05–2.23) 0.027 1.81 (1.26–2.59) 0.001
Comorbid mood disorders 4.07 (1.16–14.27) 0.028 2.60 (0.63–10.73) 0.188
Maternal psychopathology 1.04 (1.00–1.09) 0.057 1.05 (1.00–1.10) 0.052
Abbreviations: CBT, cognitive behaviour therapy; CI, confidence interval; NGF, nerve growth factor.
Bold values indicate Po0.05.
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conferring a more positive treatment response: children with
the TT genotype were 23.5% more likely to be free of their
primary anxiety diagnosis at follow-up than those children with
the CC genotype, whereas those with the CT genotype were
10.3% more likely to show remission compared with CC-
genotype children. The association between genotype and
treatment response remained significant even when other
clinically relevant covariates were included in the model. No
significant association between BDNF rs6265 genotype and
response to psychological therapy was observed, in contrast
to previous work reporting associations with antidepressant
treatment response.55 Both NGF and 5-HTTLPR were
independent predictors of anxious children’s response to
psychological therapy. However, there was no evidence for an
interaction between these markers, which is consistent with
past work.65 There were no case–control or within-family
transmission differences for either polymorphism. This is
counter to previous work reporting associations between both
BDNF and NGF polymorphisms and anxiety-related pheno-
types.
The effects of NGF genotype on psychological treatment
response were observed only at follow-up, with no significant
effects evident immediately post treatment. This mirrors the
pattern of findings we reported with 5-HTTLPR genotype.15
The period between post-treatment and follow-up is often
characterised by continued improvement, as the child con-
tinues to apply the skills learnt during therapy; thus, it is
possible that, as with the 5-HTTLPR SS genotype, having one
or more NGF T alleles influences the capacity for continued
benefit from the intervention. Further studies are necessary to
determine the precise functionality of this single nucleotide
polymorphism (or linked SNPs) and the mechanism by which
it may affect response to CBT. This is particularly pertinent
given the heterogeneity in the existing literature regarding
which allele confers the risk for anxiety and depressive
disorders.31,32 However, NGF is a plausible candidate gene
for involvement in psychological treatment response for
anxiety. It is expressed in limbic areas important for mood
and cognition and there is evidence of effects on synaptic
plasticity and neurogenesis and regulation of endocrine
responses to stress. In particular, NGF is known to act on
neurite outgrowth, making it especially well placed to
determine structural changes in neural circuitry. A rise in
serum NGF is also an indicator of positive treatment response
in generalised anxiety disorder patients following CBT.30 One
possibility is that children with the T allele may show subtle
differences in neurotrophic signalling that influence the extent
to which environmental influences bring about neuroplastic
modifications, which in turn modulate the mood.
Neuroplasticity represents a plausible biological mechan-
ism through which psychological interventions may exert
some of their therapeutic effects.66 CBT is a learning-based
intervention in which patients actively recall, reappraise and
reconstruct their experiences. The aim is to improve problem-
solving capacities, modify self-representations and regulate
distressing affective states. Significant learning experiences
of the kind undertaken during CBT may very well be
underpinned by neuroplastic modifications in brain activity
and function.66 Neuroimaging studies of psychological inter-
ventions lend weight to this hypothesis.67 Several studies
have shown that psychological interventions alter brain
function (measured by brain blood flow and oxygen/glucose
metabolism) in individuals with unipolar mood disorders68,69
and a range of anxiety disorders (OCD,70–72 panic disorder,73
social anxiety disorder,74 specific phobia75,76 and PTSD77),
with these changes consistent with the reduction in symptoms
observed following treatment. Preliminary evidence also
suggests that CBT may stimulate structural brain alterations
reflective of neuroplasticity. After 16 sessions of CBT, women
with chronic fatigue syndrome showed small increases in grey
matter of the lateral prefrontal cortex.78 However, the study of
changes in brain structure and function across psychological
interventions is relatively new and many findings require
replication and methodological improvements before defini-
tive conclusions can be made regarding the neural effects of
these interventions.67 In particular, it remains to be deter-
mined whether CBT has a causal influence on brain structure
and function.
The present findings may have important clinical implica-
tions. These and our previous data,15 if replicated, suggest
that knowledge of genetic markers could be used to inform
clinical treatment decisions for psychotherapeutic as well as
pharmacological interventions. However, to do so, genetic
markers will need to yield sufficiently large effects to make a
Table 4 Interaction between NGF rs6330 and 5-HTTLPR in predicting primary anxiety disorder response (NGF rs6330 coded as CC¼1; CT¼ 0, TT¼1;
5-HTTLPR coded as LL/LS¼ 0; SS¼1)
Predictor variable Model 1 Model 2 Model 3
OR (95% CI) P OR (95% CI) P OR (95% CI) P
NGF rs6330 0.58 (0.40–0.84) 0.004 0.57 (0.38–0.85) 0.006 0.59 (0.39–0.89) 0.013
5-HTTLPR 0.38 (0.18–0.80) 0.011 0.39 (0.18–0.85) 0.017 0.36 (0.16–0.82) 0.015
rs63305-HTTLPR 1.12 (0.40–3.12) 0.823
Time (linear) 0.18 (0.02–1.76) 0.140 0.18 (0.02–1.76) 0.141 0.41 (0.04–4.85) 0.481
Time2 (quadratic) 1.30 (0.95–1.78) 0.106 1.30 (0.95–1.78) 0.105 1.15 (0.82–1.62) 0.422
Age 0.90 (0.78–1.05) 0.174 0.90 (0.78–1.04) 0.168 0.91 (0.77–1.07) 0.261
Gender 1.16 (0.69–1.95) 0.580 1.16 (0.69–1.95) 0.578 1.33 (0.74–2.37) 0.339
Site 1.08 (0.56–2.10) 0.809 1.08 (0.56–2.10) 0.812 0.95 (0.43–2.10) 0.891
Pre-treatment severity 1.44 (0.98–2.12) 0.061
Comorbid mood disorders 3.26 (0.93–11.38) 0.064
Maternal psychopathology 1.04 (1.00–1.09) 0.066
Abbreviations: CI, confidence interval; NGF, nerve growth factor.
Bold values indicate Po0.05.
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clinically meaningful contribution to psychological treatment
response prediction. Recent work has shown using simulation
data that for a genetic marker with a minor allele frequency
(MAF) of 30% (that approximates the MAF for rs6330), a per-
allele difference of 2.4 points on the Hamilton Rating Scale for
Depression would be required to explain 6.3% of the variance
in outcome in an antidepressant trial.79 Only then would the
genetic marker be considered a clinically meaningful predictor
of treatment outcome. The simulations are also extended to
categorical outcomes (for example, remission status) and
suggest that pseudo r2 values can be approximately
translated to the clinically meaningful effect size measure of
number needed to assess (NNA). For the clinical significance
criterion of 6.3%, this corresponds to a NNA of 3: meaning that
for every three patients assessed for a genetic marker, one
significantly more accurate prediction of outcome can be
made. In the present data, a model containing only NGF
rs6330 genotype yielded a pseudo r2 estimate of 0.023 and an
area under the curve (AUC) of 0.5938. Converting AUC to
NNA using the methods outlined79 (see also Kraemer and
Kupfer80) produces an NNA of 5.33. This suggests that for
every five patients assessed for rs6330, one significantly
more accurate prediction of outcome could be made.
However, our summary statistic of choice is the percentage
difference in treatment response between genotype groups:
compared with individuals with no copies of the T allele, 23.5%
more children with the TT genotype had a positive treatment
response. We consider this to be indicative of a clinically
meaningful effect. However, we also concur with the views of
others79 that clinically significant prediction by genetic
markers is likely to be best achieved by combining multiple
genetic markers (perhaps in combination with clinical pre-
dictors) into predictive indices or algorithms.
This study has several limitations worthy of consideration.
First, there is no independent replication, so these results
should be considered preliminary. Although the main findings
were consistent in direction in both the white subset and the
entire sample, giving us confidence in the veracity of the
results, some of the findings reported do not survive multiple
testing corrections. Following conservative correction for all
primary and secondary analyses performed in this and our
previous paper, none of the analyses reported survived
multiple testing correction. In our lab, we are in the process
of working towards obtaining a replication sample. We intend
to explore a limited number of additional plausible candidate
markers in this original data set. This manuscript outlines the
analyses we have performed to date and we will continue to
take this approach going forwards. Second, the sample size,
although large for a child anxiety treatment trial, is relatively
small for a genetic association study. This may have reduced
power to detect significant effects in some of our analyses.
Third, the functional relevance of the NGF SNP (rs6330)
remains underspecified, particularly with regard to the
mechanisms by which the T allele may confer a benefit in
terms of treatment response. We also limited our investiga-
tions to just two SNPs, each previously associated with
anxiety phenotypes. However, it remains plausible that other
NGF and BDNF variants may contribute both to susceptibility
to anxiety disorders and to psychological therapy response.
Fourth, our main analyses were performed on a subset who
self-reported having four white European ancestry grand-
parents. However, without the benefit of ancestrally informa-
tive markers, it is not possible to eliminate the potential risk of
hidden population substructures.
In summary, allelic variation in NGF rs6330 significantly
predicted response to CBT in children with a primary anxiety
diagnosis. These findings show that interactions between
genetic variation and environmental experiences (here,
psychological therapy) can influence not only the develop-
ment but also the remission of psychiatric outcomes. Genetic
predictors of treatment response may prove to be particularly
informative given that they can be measured with little error
and remain stable over time. Knowing an anxious child’s
genetic makeup with regard to NGF rs6330 and 5-HTTLPR
genotype has predictive power for treatment prognosis, above
and beyond ‘traditional’ clinical predictors such as disorder
severity, comorbid mood disorders and parental psycho-
pathology. This information could be beneficial in helping to
decide whether a child is likely to benefit from standard CBT
alone or whether an enhanced treatment is required in order to
maximise the chance of them improving.
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